Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glycoprotein hormone structure-function and analog design.

I Boime1, D Ben-Menahem

  • 1Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Recent Progress in Hormone Research
|November 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model.

Animal reproduction science·2009
Same author

Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.

Human reproduction update·2009
Same author

The expanding role of recombinant gonadotropins in assisted reproduction.

Reproduction in domestic animals = Zuchthygiene·2008
Same author

The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: induction of ovulation, hormone profiles, and inter-ovulatory intervals.

Domestic animal endocrinology·2007
Same author

Strategies for construction of luteinizing hormone beta subunit analogs with carboxyl terminal extensions in non-primate, non-equid mammalian species.

Molecular and cellular endocrinology·2006
Same author

Homologous and heterologous carboxyl terminal peptide (CTP) linker sequences enhance the secretion of bioactive single-chain bovine LH analogs.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2006

Scientists engineered single-chain analogs of hormones like follicle-stimulating hormone (FSH) by fusing subunits. These novel hormone analogs demonstrate enhanced biological activity and longer half-lives, offering potential for improved therapeutics.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Molecular Biology

Background:

  • Hormones like human chorionic gonadotropin (hCG), luteinizing hormone, follicle-stimulating hormone (FSH), and thyrotropin (TSH) share a common alpha subunit but have distinct beta subunits.
  • The carboxy-terminal extension (CTP) of the hCG beta subunit is crucial for its extended biological half-life.
  • FSH's short half-life presents a clinical challenge for infertility treatments.

Purpose of the Study:

  • To investigate the potential of creating single-chain hormone analogs using recombinant DNA technology.
  • To enhance the biological half-life and potency of hormones like FSH.
  • To explore the functional consequences of genetically fusing hormone subunits.

Main Methods:

  • Utilized recombinant DNA techniques to construct single-chain analogs, including fusing the CTP to the FSH beta subunit and creating an hCG beta-alpha chimera.

Related Experiment Videos

  • Assessed the secretion, biological activity (in vitro and in vivo), and half-life of the engineered single-chain hormone analogs.

    • Main Results:

    • Fusing CTP to the FSH beta subunit resulted in a threefold increase in in vivo potency.
    • A single-chain chimera of hCG beta and alpha subunits was efficiently secreted and showed increased biological activity.
    • Single-chain FSH analogs retained in vivo activity, suggesting longer biological half-lives due to preventing subunit dissociation.

    Conclusions:

    • Single-chain hormone analogs, engineered through subunit fusion, can maintain or enhance biological activity.
    • The incorporation of CTP and the creation of single-chain structures represent promising strategies for developing more stable and potent hormone-based therapeutics.
    • These engineered analogs serve as a foundation for developing effective agonists and antagonists for various hormonal applications.